Brief: Isofol Medical: More Patients To Benefit From Arfolitixorin

Isofol Medical AB (publ)

30/03/2020 07:10

March 30 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * GENE EXPRESSION DATA FROM NEW ANALYSIS METHOD SUPPORTS
THAT A
LARGER PROPORTION OF PATIENTS WILL BENEFIT FROM ARFOLITIXORIN
    * DATA FROM OPTIMIZED GENE EXPRESSION METHOD VALIDATED BY
TATAA
BIOCENTER AB, COMPARED WITH DATA BASED ON PRE-COMMERCIAL GENE
EXPRESSION METHOD, SHOWS AN INCREASE OF PROPORTION OF PATIENTS
HAVING LOWER ABCC3 GENE EXPRESSION I.E. 66.6% TO 75%
    * LARGER PROPORTION OF PATIENTS, I.E. THOSE WITH LOW ABCC3
EXPRESSION, COULD HAVE SIGNIFICANT BETTER EFFECT OF
ARFOLITIXORIN THAN CURRENTLY USED PRODRUGS (LEUCOVORIN) ON PFS
AND ULTIMATELY ON OVERALL SURVIVAL
    * PROGRESSION FREE SURVIVAL (PFS) BENEFIT FOR THOSE WITH A
HIGH
ABCC3 GENE EXPRESSION HAS INCREASED BY 1.1 MONTHS, NOW SHOWING A
4.7 MONTH DIFFERENCE FROM THOSE WITH A LOW ABBC3 GENE EXPRESSION

Source text for Eikon:  ID:nWkr3ckQsH 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))